PC
UTHR icon

PA Capital’s United Therapeutics UTHR Stock Holding History

PA Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,952
Closed -$659K – 199
2020
Q1 		$659K Sell
6,952
-3,015
-30% -$287K 0.58% 69
2019
Q4 		$878K Buy
9,967
+1,808
+22% +$159K 0.78% 49
2019
Q3 		$651K Buy
+8,159
New +$657K 0.64% 61

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PA Capital's UTHR Position: Q2 2020 in Review

PA Capital sold out of United Therapeutics (UTHR) in Q2 2020, closing a stake of 6,952 shares — an estimated $659K sold.

PA Capital first reported a position in UTHR in Q3 2019 and held it in 3 quarters. The position peaked at $878K in Q4 2019. 349 funds tracked by Wall St. Rank hold UTHR as of Q2 2020.

  • PA Capital reported no remaining United Therapeutics position as of Q2 2020 after selling out during the quarter.
  • PA Capital sold 6,952 United Therapeutics shares in Q2 2020, an estimated $659K.
  • PA Capital first reported a position in United Therapeutics in Q3 2019 and held it in 3 quarters.
  • PA Capital's United Therapeutics position peaked at $878K in Q4 2019.
  • 349 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2020.

Based on PA Capital's 13F filing for Q2 2020, filed 13 Aug 2020.